Compare · Head-to-head
Cerebrolysin vs Thymosin Beta-4.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Thymosin Beta-4, then use the table to confirm fit.
Thymosin Beta-4 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
Cerebrolysin
Porcine neuropeptide mixture used in some international stroke and cognition programs, but not FDA-approved.
01 · At a glance
| Decision factor | Cerebrolysin | Thymosin Beta-4 |
|---|---|---|
| Primary fit | tissue repair & recovery and cognitive & neuroprotection comparisons | tissue repair & recovery and immune support comparisons |
| Evidence | Tier C | Tier B-C |
| Risk | medium | med-high |
| Experience level | advanced | intermediate |
| Budget tier | premium | mid |
| Administration route | intravenous, intramuscular | topical, subcutaneous |
02 · Use case & timing
| Decision factor | Cerebrolysin | Thymosin Beta-4 |
|---|---|---|
| Goal fit | Tissue Repair & Recovery, Cognitive & Neuroprotection | Tissue Repair & Recovery, Immune Support |
| What users compare it for | Possible neurorecovery or cognitive-support effects in select clinical settings, though evidence quality is heterogeneous. | Ophthalmic: improved corneal epithelial healing. Systemic: wound healing signals in preclinical models. |
| Onset timeline | Clinical outcomes are tracked over days to weeks in stroke or cognition programs. | Corneal healing studies: days to weeks; systemic repair claims are less well-timed. |
| Main tradeoff | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | Cerebrolysin | Thymosin Beta-4 |
|---|---|---|
| Adverse effects | Headache, fever, nausea, restlessness, injection reactions, and rare hypersensitivity are reported. | Human ophthalmic safety reported as acceptable in trials; systemic safety requires caution. |
| Contraindications | Use caution in porcine-protein sensitivity and where product provenance cannot be established. | Limited formal contraindication data. |
| Interaction notes | No strong interaction map; combining with other CNS-active research compounds increases interpretation difficulty. | Limited formal interaction studies; treat as unknown outside studied settings. |
| Regulatory status | Not approved | Investigational |
| FDA flag | FDA status unclear | FDA compounding caution |
| WADA status | Not listed | WADA S2 |
04 · Age & monitoring
| Decision factor | Cerebrolysin | Thymosin Beta-4 |
|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | Cerebrolysin | Thymosin Beta-4 |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | $192.00 |
| Estimated monthly cost | No reliable estimate yet | $96.00 |
| Cost confidence | No estimate | High confidence |
06 · Before you buy
| Decision factor | Cerebrolysin | Thymosin Beta-4 |
|---|---|---|
| Tracked vendor listings | 0 listings | 1 listing |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.